Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly

Purpose Recent data indicate that extended dosing intervals (EDIs) with lanreotide autogel 120 mg are effective and well-received among patients with acromegaly who have achieved biochemical control with monthly injections of long-acting somatostatin analogues (SSAs). We further evaluated the effect...

Full description

Bibliographic Details
Authors: Bernabeu, I, Fajardo, C, Marazuela, M, Cordido, F, Venegas, EM, de Pablos-Velasco, P, Maroto, GP, Olvera, MP, de Paz, IP, Carvalho, D, Romero, C, De la Cruz, G, Escola, CA
Format: article
Status:Published version
Publication Date:2020
Country:España
Institution:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Repository:r-FISABIO. Repositorio Institucional de Producción Científica
OAI Identifier:oai:fisabio.fundanetsuite.com:p9238
Online Access:https://fisabio.portalinvestigacion.com/publicaciones/9238
Access Level:Open access
Keyword:Acromegaly
Lanreotide
Insulin-like growth factor 1
Somatostatin
Growth hormone
id ES_620363db8b2f171eaef2ef3ce7b31e92
oai_identifier_str oai:fisabio.fundanetsuite.com:p9238
network_acronym_str ES
network_name_str España
repository_id_str
spelling Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegalyBernabeu, IFajardo, CMarazuela, MCordido, FVenegas, EMde Pablos-Velasco, PMaroto, GPOlvera, MPde Paz, IPCarvalho, DRomero, CDe la Cruz, GEscola, CAAcromegalyLanreotideInsulin-like growth factor 1SomatostatinGrowth hormonePurpose Recent data indicate that extended dosing intervals (EDIs) with lanreotide autogel 120 mg are effective and well-received among patients with acromegaly who have achieved biochemical control with monthly injections of long-acting somatostatin analogues (SSAs). We further evaluated the effectiveness of lanreotide autogel 120 mg delivered at EDIs (>4 weeks) in routine clinical practice. Methods Cross-sectional, multicentre, observational study conducted to determine the effectiveness-measured by control of serum insulin-like growth factor 1 (IGF-1)-of lanreotide autogel 120 mg at dosing intervals >4 weeks for >= 6 months in selected patients with acromegaly treated in routine clinical practice (NCT02807233). Secondary assessments included control of growth hormone (GH) levels, treatment adherence, patient satisfaction, and quality of life (QoL) using validated questionnaires (EQ-5D, AcroQoL, and TSQM-9). Patients who received radiotherapy within the last 6 months were excluded. Results Among 109 patients evaluated, mean (SD) age was 59.1 (13.2) years. IGF-1 values were normal (mean [SD]: 175.0 [74.5], 95% CI: 160.8 -189.1) in 91.7% of cases and normal in 91.4% of patients without previous radiotherapy treatment (n = 81). GH levels were <= 2.5 and <= 1 ng/mL, respectively, in 80.6% and 58.3%. Most patients were treated either every 5-6 (57.8%) or 7-8 weeks (38.5%), with 2.8% treated greater than every 8 weeks. The mean AcroQoL score was 63.0 (20.1). The mean global treatment satisfaction score (TSQM-9) was 75.1 (16.6). Treatment adherence (defined as no missed injections) was 94.5%. Conclusion Lanreotide autogel 120 mg at intervals of >4 weeks provided IGF-1 control in more than 90% of patients with acromegaly. Treatment satisfaction and adherence were good. These findings support use of extended dosing intervals in patients who have achieved good biochemical control with long-acting SSAs.SPRINGER2020info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://fisabio.portalinvestigacion.com/publicaciones/9238ENDOCRINEISSN: 1355008XISSNe: 15590100reponame:r-FISABIO. Repositorio Institucional de Producción Científicainstname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)Inglésinfo:eu-repo/semantics/openAccessoai:fisabio.fundanetsuite.com:p92382026-06-11T12:45:17Z
dc.title.none.fl_str_mv Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly
title Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly
spellingShingle Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly
Bernabeu, I
Acromegaly
Lanreotide
Insulin-like growth factor 1
Somatostatin
Growth hormone
title_short Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly
title_full Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly
title_fullStr Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly
title_full_unstemmed Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly
title_sort Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly
dc.creator.none.fl_str_mv Bernabeu, I
Fajardo, C
Marazuela, M
Cordido, F
Venegas, EM
de Pablos-Velasco, P
Maroto, GP
Olvera, MP
de Paz, IP
Carvalho, D
Romero, C
De la Cruz, G
Escola, CA
author Bernabeu, I
author_facet Bernabeu, I
Fajardo, C
Marazuela, M
Cordido, F
Venegas, EM
de Pablos-Velasco, P
Maroto, GP
Olvera, MP
de Paz, IP
Carvalho, D
Romero, C
De la Cruz, G
Escola, CA
author_role author
author2 Fajardo, C
Marazuela, M
Cordido, F
Venegas, EM
de Pablos-Velasco, P
Maroto, GP
Olvera, MP
de Paz, IP
Carvalho, D
Romero, C
De la Cruz, G
Escola, CA
author2_role author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Acromegaly
Lanreotide
Insulin-like growth factor 1
Somatostatin
Growth hormone
topic Acromegaly
Lanreotide
Insulin-like growth factor 1
Somatostatin
Growth hormone
description Purpose Recent data indicate that extended dosing intervals (EDIs) with lanreotide autogel 120 mg are effective and well-received among patients with acromegaly who have achieved biochemical control with monthly injections of long-acting somatostatin analogues (SSAs). We further evaluated the effectiveness of lanreotide autogel 120 mg delivered at EDIs (>4 weeks) in routine clinical practice. Methods Cross-sectional, multicentre, observational study conducted to determine the effectiveness-measured by control of serum insulin-like growth factor 1 (IGF-1)-of lanreotide autogel 120 mg at dosing intervals >4 weeks for >= 6 months in selected patients with acromegaly treated in routine clinical practice (NCT02807233). Secondary assessments included control of growth hormone (GH) levels, treatment adherence, patient satisfaction, and quality of life (QoL) using validated questionnaires (EQ-5D, AcroQoL, and TSQM-9). Patients who received radiotherapy within the last 6 months were excluded. Results Among 109 patients evaluated, mean (SD) age was 59.1 (13.2) years. IGF-1 values were normal (mean [SD]: 175.0 [74.5], 95% CI: 160.8 -189.1) in 91.7% of cases and normal in 91.4% of patients without previous radiotherapy treatment (n = 81). GH levels were <= 2.5 and <= 1 ng/mL, respectively, in 80.6% and 58.3%. Most patients were treated either every 5-6 (57.8%) or 7-8 weeks (38.5%), with 2.8% treated greater than every 8 weeks. The mean AcroQoL score was 63.0 (20.1). The mean global treatment satisfaction score (TSQM-9) was 75.1 (16.6). Treatment adherence (defined as no missed injections) was 94.5%. Conclusion Lanreotide autogel 120 mg at intervals of >4 weeks provided IGF-1 control in more than 90% of patients with acromegaly. Treatment satisfaction and adherence were good. These findings support use of extended dosing intervals in patients who have achieved good biochemical control with long-acting SSAs.
publishDate 2020
dc.date.none.fl_str_mv 2020
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://fisabio.portalinvestigacion.com/publicaciones/9238
url https://fisabio.portalinvestigacion.com/publicaciones/9238
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv SPRINGER
publisher.none.fl_str_mv SPRINGER
dc.source.none.fl_str_mv ENDOCRINE
ISSN: 1355008X
ISSNe: 15590100
reponame:r-FISABIO. Repositorio Institucional de Producción Científica
instname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
instname_str Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
reponame_str r-FISABIO. Repositorio Institucional de Producción Científica
collection r-FISABIO. Repositorio Institucional de Producción Científica
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869409463359766528
score 15,811543

Similar Items